new drug that melts tumors and avoids surgery and chemotherapy
Pembrolizumab will revolutionize the fight against cancer. A drug belonging to the so-called “monoclonal antibodies”, which melts tumors, which allows you to cure intestinal cancer, which can replace surgery. This miracle injection was created by three universities and four hospitals in the UK.
This drug attack and block a specific protein found on the surface of immune cells, and then find and destroy cancer cellsExplain The keeper. Its delivery to 32 patients with stage 2 or 3 bowel cancer increased the number of recoveries. The findings were presented at the annual meeting of the American Society of Clinical Oncology (ASCO), the largest cancer conference in the world, the British newspaper reported.
“The results were very impressive,” said Professor Mark Saunders, consultant clinical oncologist at Christie. The keeper. “Immunotherapy before surgery could be a game changer” for patients with bowel cancer. prevents them from receiving chemotherapywhich often has more side effects,” he says.
Neoadjuvant pembrolizumab stratified by TMB for stage 2 or 3 high-risk MSI-high CRC #ASCO24
🔎NEOPRISM-CRC, 32 points
👉only 1 TMB-low
👉62% rT1a/b
👉pCR: 59%
👉Do not relapse
🧐a safe and efficient translation program is expected@myESMO pic.twitter.com/PXpSwWqpFi— Arndt Vogel (@ArndtVogel) June 2, 2024
The companies behind this product are University College London and University College London Hospital, Christie NHS Foundation Trust (Manchester), St James’s University Hospital (Leeds), University Hospital Southampton and the University of Glasgow.
This type of cancer is on the rise, with more than 1.9 billion new cases and more than 900,000 deaths annually, according to the World Health Organization (WHO). With these figures, it has established itself as the second leading cause of cancer deaths in the world.
The study, funded by Merck Sharp and Dohme and sponsored by University College London, shows that 59% of patients had no signs of cancer after treatment with pembrolizumab, and in the remaining 41% the cancer was removed during surgery. All patients in the study were cancer-free after treatment.